In 2013, the Menopause Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association published the “Standardized Procedures for Menopause-related Hormone Supplementation Therapy” and the “Clinical Application Guidelines for Menopause Management and Hormone Supplementation Therapy (2012 Edition)”, and Prof. Yu Qi also published a review “Menopause – an Old Concept, a Real Problem”. It is interesting to note that the January issue of Obstet Gynecol also published guidelines from the American College of Obstetricians and Gynecologists on the symptoms of menopause, which can be read for reference. For some women, menopause is an event that goes virtually unnoticed, with their periods ending peacefully and without any impact on their lives. For most women, however, this phase has a significant physical, psychological and emotional impact. The medical community’s attitude toward menopause has changed several times, with John Friend’s 18th century opinion that menopause is beneficial to a woman’s health as she ages. In 1941, Dr. Novak wrote in his NOVAK Gynecology (1st ed.) that “for many women the onset of menopause is a boon that will markedly improve their general health and well-being”. In China, as early as the Spring and Autumn Period, the important medical text “Suwen? In the Spring and Autumn period, the important medical text “Suwen?” of the Nei Jing described the situation as follows: “The seventh year of the Ren pulse is deficient, the Taichong pulse is weak, the Tiankui is exhausted, and the earth is blocked, so the form is bad and there is no child.” The description of “bad form” here could not be more apt for postmenopausal women. Before the 1930s, however, menopause was not a widespread phenomenon and did not cause enough health problems to attract the attention of national health authorities, medical professionals, and society, as the average human life expectancy was only about 30 years. As our society ages, the number of people entering menopause is becoming larger and larger. Menopause is a life-giving phenomenon, but it has become a common phenomenon in the last 70 years or so in the long history of mankind. Menopause is a product of the progressive increase in life expectancy of modern humans, a state that has been overlooked in evolution. Menopause is essentially the failure of the ovaries, an essential organ for women, and has long been of concern to professionals and the general public because of the multiple symptoms associated with menopause, which involve multiple systems, and because of its association with many chronic diseases of the elderly, such as osteoporosis, which are a major drain on health care resources. According to a United Nations study, by 2011, 157 million women were between the ages of 45 and 64, and it is expected that by 2020, this population will reach 197 million. The most effective treatment for menopause-related symptoms is hormone replacement therapy (HRT), which has been studied and practiced by generations of scholars for decades and has been proven to be effective in relieving menopause-related symptoms, as well as in early menopause (the “window” of treatment). The use of HRT can also prevent the occurrence of chronic diseases in old age to a certain extent. Based on this demand, the Menopause Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association has formulated the “Guidelines for the Clinical Application of HRT in the Transitional and Postmenopausal Periods”, which has been updated and revised three times. However, during the actual implementation of the guidelines, it was found that the current situation in China is that clinicians are still inexperienced in the rational application of HRT, and the available literature is mostly based on relevant studies and lacks guidance for clinical practice, which cannot comprehensively cover the diverse patient demands in clinical practice. Therefore, there is a growing demand for a guiding clinical practice and a systematic and comprehensive introduction to the standardized treatment procedure of HRT. In the 2012 version of the guideline, it is clearly stated that Level A evidence of HRT includes the following three major symptoms: menopause-related symptoms (menstrual disorders, hot flashes, excessive sweating, sleep disorders, fatigue, mood disorders such as agitation, irritability, anxiety, nervousness or depression); symptoms related to genitourinary tract atrophy (vaginal dryness, pain, painful intercourse, recurrent vaginitis, difficulty in urination, recurrent urinary tract infections, nocturnal urination, urinary tract atrophy, etc.). infections, nocturia, frequency and urgency); and low bone mass and osteoporosis (including the presence of risk factors for osteoporosis and postmenopausal osteoporosis). The guidelines state that the decision to continue HRT for women aged <60>60 years can be based on an overall benefit-to-risk analysis and that there is no evidence to set a year limit for the continued use of HRT. The guidelines emphasize that estrogen and/or progestin supplementation for 5 years does not increase a patient’s lifetime risk of breast cancer. The guidelines re-emphasize that progestin should be added to HRT for women with a uterus.